▽NCCN Clinical Practice Guidelines in Oncology
●01/07 05:50
Version: 2.2025

▽omacetaxine - PubMed - NCBI
●01/07 04:55
2024 502025 2

▽PKC412 - PubMed - NCBI
●01/07 04:44
2024 822025 3Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Luskin MR, DeAngelo DJ. Luskin MR, et al. Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30. Expert Rev Hematol. 2017. PMID: 29069942 Review.Areas covered: Standard treatment of FLT3-mutant AML and outcomes. Early clinical developm

▽clofarabine - PubMed - NCBI
●01/07 04:40
Clofarabine.Pui CH, Jeha S, Kirkpatrick P. Pui CH, et al. Nat Rev Drug Discov. 2005 May;4(5):369-70. doi: 10.1038/nrd1724. Nat Rev Drug Discov. 2005. PMID: 15902772 No abstract available.Clofarabine: past, present, and future.Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Kantarjian HM, et al. Leuk Lymphoma. 2007 Oct;48(10):1922-30. doi: 10.1080/10428190701545644. Leuk Lymphoma. 2007. PMID:

▽romidepsin
●01/07 04:16
Romidepsin for the treatment of non-Hodgkin's lymphoma.Yazbeck VY, Grant S. Yazbeck VY, et al. Expert Opin Investig Drugs. 2015;24(7):965-79. doi: 10.1517/13543784.2015.1041586. Epub 2015 May 4. Expert Opin Investig Drugs. 2015. PMID: 25936363 Review.Romidepsin antagonism with CHOEP.Ramdial JL, Valdez BC, Andersson BS, Nieto Y. Ramdial JL, et al. Leukemia. 2023 May;37(5):1160-1161. doi: 10.1038